Read more

May 30, 2024
1 min read
Save

ARVO 2024: Possible link between long COVID, vision changes tops Healio’s written items

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

As Healio’s coverage of the Association for Research in Vision and Ophthalmology meeting winds down, catch up on this year’s most popular articles.

Hot topics include a possible link between vision changes and a severe form of long COVID and ChatGPT’s underwhelming success rate when attempting to pass an ophthalmology board exam.

Graphic distinguishing meeting news
As Healio’s coverage of the Association for Research in Vision and Ophthalmology meeting winds down, catch up on this year’s most popular articles.

Vision changes in patients with long COVID may reflect severe disease phenotype

Persistent vision changes were found to be a symptom of severe forms of long COVID and were associated with worse clinical manifestations, according to a poster presentation. Read more.

ChatGPT would not pass ophthalmology board exam

If ChatGPT were to take an ophthalmology board-style exam, it would not pass, even if given feedback and a second chance, according to a poster presentation. Read more.

Study examines national estimates of new onset vision impairment in older patients

Despite a high prevalence of visual impairment among older patients, some make improvements year-over-year, according to a study. Read more.

Phase 2 nonproliferative diabetic retinopathy trial misses primary endpoint

The phase 2 PAVIA trial investigating Duravyu, previously known as EYP-1901, for the treatment of nonproliferative diabetic retinopathy did not meet its primary endpoint, according to a press release from EyePoint Pharmaceuticals. Read more.

Faricimab achieves inactive disease in veteran population with AMD

Patients with age-related macular degeneration in a veteran population experienced an increase in inactive disease after treatment with faricimab, according to a poster presentation. Read more.